- HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
- HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
- HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
- HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
- HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
- HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- HilleVax to Present at Upcoming Investor Conferences
- HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
- HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
More ▼
Key statistics
On Thursday, Hillevax Inc (HLVX:NSQ) closed at 13.08, 31.59% above the 52 week low of 9.94 set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.12 |
---|---|
High | 14.45 |
Low | 12.86 |
Bid | 5.26 |
Offer | 20.79 |
Previous close | 13.08 |
Average volume | 197.60k |
---|---|
Shares outstanding | 49.72m |
Free float | 46.24m |
P/E (TTM) | -- |
Market cap | 650.35m USD |
EPS (TTM) | -3.29 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼